CoChat

Creatine for amyotrophic lateral sclerosis/motor neuron disease

Pastula, Daniel M, Moore, Dan H, Bedlack, Richard S · 2012 · Cochrane Database of Systematic Reviews
Cited by 33

The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.

Abstract

Background Creatine, a naturally‐occurring nitrogenous organic acid involved in adenosine triphosphate (ATP) production, has been shown to increase survival in mouse models of amyotrophic lateral sclerosis (ALS), also known as motor neuron disease (MND). Results from human trials, however, have been mixed. Given conflicting results regarding the efficacy of creatine, we conducted a systematic review, which was updated in 2012. Objectives To systematically examine the efficacy of creatine efficacy in prolonging ALS survival and in slowing ALS disease progression. Search methods We searched the Cochrane Neuromuscular Disease Group Specialized Register (16 July 2012), CENTRAL (2012, issue 7 in the Cochrane Library), MEDLINE (January 1966 to July 2012) and EMBASE (January 1980 to July 2012) for any trial involving creatine in the treatment of ALS. We also contacted experts in the field for any additional studies. Selection criteria Randomized trials of treatment with creatine or placebo in patients diagnosed with ALS. Our primary outcome was tracheostomy‐free survival time; secondary outcomes were ALS progression as measured by changes in ALS functional rating revised scores (ALSFRS‐R) and per cent predicted forced vital capacity (FVC) over time. Data collection and analysis Two authors independently selected studies, assessed risk of bias and extracted data. We obtained and analyzed individual participant data from each study. Main results We included three trials involving 386 participants randomized to either creatine 5 to 10 g per day or placebo. When we updated the searches in 2012 we found no additional trials. Creatine was reportedly well‐tolerated in all three included studies, with no evidence of renal failure or serious adverse events specifically attributable to creatine. Using a pooled log‐rank statistical test, we found no statistical difference in survival between the placebo and creatine groups across all three studies (Chi2 = 0.09, P = 0.76). In addition, we found no statistical difference in ALSFRS‐R slopes between the two groups across all three studies using a pooled linear mixed‐effects model (slope difference of +0.03 ALSFRS‐R/month in the creatine group; P = 0.76). Interestingly, there was a trend towards slightly worsened FVC slope in the creatine group (slope difference of ‐0.63 FVC/month in the creatine group) using a pooled linear mixed‐effects model across the two studies which included FVC as an outcome, but this difference was not statistically significant (P = 0.054). Authors' conclusions In patients already diagnosed with clinically probable or definite ALS, creatine at doses ranging from 5 to 10 g per day did not have a statistically significant effect on survival, ALSFRS‐R progression or percent predicted FVC progression.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1002/14651858.cd005225.pub3

Cites

5 of 5 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Cited by

See all 33

Metadata

Authors
Pastula, D. M., Moore, D. H., & Bedlack, R. S.
Venue
Cochrane Database of Systematic Reviews
Publisher
Wiley
Published
2012-12-12
Volume
2012
Issue
12
ISSN
  • 1361-6137 (ISSN-L)
  • 1465-1858
OpenAlex
W4244978489
Cited by
33
References
5
FWCI
1.31
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.